SCHEMBL2929533

SCHEMBL2929533

CCOC(=O)c1conc1-c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 3/20 0.52
TARBP2 Q15633 1/20 0.50
HSD17B10 Q99714 1/20 0.48
GCGR P47871 1/20 0.47
ALPL P05186 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
POLB P06746 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.46
GABRA2 P47869 2/20 0.45
GABRB2 P47870 2/20 0.45
MAPK1 P28482 1/20 0.45
IDO1 P14902 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
PRKCZ Q05513 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8163709 0.87 TSHR (0.44) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1776614 0.86 KDM4E (0.51) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5772148 0.86 ALDH1A1 (0.53) SMN1; SMN2KDM4EALDH1A1HPGDTARBP2
SCHEMBL11396935 0.86 ALDH1A1 (0.56) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5774923 0.85 TEAD2 (0.54) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5771314 0.85 TEAD2 (0.48) SMN1; SMN2KDM4EALDH1A1HPGDTARBP2
SCHEMBL11395576 0.84 JAK2 (0.55) SMN1; SMN2KDM4EALDH1A1HPGDMAPT
SCHEMBL27946184 0.84 SLC6A3 (0.51) SMN1; SMN2KDM4EALDH1A1NPC1RAB9A
SCHEMBL5773409 0.83 MAPT (0.49) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL5773232 0.82 TEAD2 (0.46) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2229383-B1 ISOXAZOLO-PYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-01-18 EP disclosed
EP-2768827-B1 PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS HOFFMANN LA ROCHE (CH) 2016-11-23 EP disclosed
EP-2767536-B1 Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE (CH) 2015-09-02 EP disclosed
US-9073908-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2015-07-07 US disclosed
EP-2227467-B1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-12-31 EP disclosed
US-8877782-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 US disclosed
US-8877783-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 US disclosed
US-8846719-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-09-30 US disclosed
EP-2768827-A1 PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-27 EP disclosed
EP-2767536-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2014-08-20 EP disclosed
US-7902201-B2 Isoxazolo-pyrazine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-03-08 US disclosed
US-20100256154-A1 ISOXAZOLO-PYRAZINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
EP-2229383-A1 ISOXAZOLO-PYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
EP-2227467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
WO-2009071476-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-11 WO disclosed
WO-2009071464-A1 ISOXAZOLO-PYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-11 WO disclosed
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES ROCHE PALO ALTO LLC 2009-06-04 US disclosed
US-4261728-A PREEMERGENT ACTIVITY MONSANTO COMPANY (US) 1981-04-14 US disclosed
US-4187099-A 3-Aryl-4-isothiazolecarboxylic acid and 3-aryl-4-isoxazolecarboxylic acid derivatives and their use as herbicides MONSANTO COMPANY (US) 1980-02-05 US disclosed
US-4144047-A SOYBEANS MONSANTO COMPANY (US) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES GABRA5, GABRA1, CHRNA5 SMN1; SMN2 3318/4885KDM4E 1485/4885ALDH1A1 938/4885
US-20100256154-A1 ISOXAZOLO-PYRAZINE DERIVATIVES GABRA5, GRIK5, GABRA4 SMN1; SMN2 3354/4885KDM4E 1822/4885ALDH1A1 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.